634197-80-1

Basic information

• Product Name: 2-AMino-5-benzyloxy-4-Methoxy-benzoic acid benzyl ester hydrochloride
• Synonyms: 2-AMino-5-benzyloxy-4-Methoxy-benzoic acid benzyl ester hydrochloride;Benzyl 2-amino-5-(benzyloxy)-4-methoxybenzoate hydrochloride
• CAS NO: 634197-80-1
• Molecular Formula: C₂₂H₂₁NO₄
• Molecular Weight: 399.86738
• Mol File: 634197-80-1.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 544.7±45.0 °C(Predicted)
• Appearance: /
• Density: 1 +-.0.06 g/cm3(Predicted)
• PKA: 2?+-.0.10(Predicted)
• CAS DataBase Reference: 2-AMino-5-benzyloxy-4-Methoxy-benzoic acid benzyl ester hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: 2-AMino-5-benzyloxy-4-Methoxy-benzoic acid benzyl ester hydrochloride(634197-80-1)
• EPA Substance Registry System: 2-AMino-5-benzyloxy-4-Methoxy-benzoic acid benzyl ester hydrochloride(634197-80-1)

Safety Data

• Hazardous Substances Data: 634197-80-1(Hazardous Substances Data)

Usage

Chemical Structure

2-Amino-5-benzyloxy-4-methoxy-benzoic acid benzyl ester
Hydrochloride salt

Physical Appearance

White to off-white solid

Solubility

Soluble in organic solvents

Derivative

Benzyl ester of 2-amino-5-benzyloxy-4-methoxy-benzoic acid

Derived From

Benzoic acid

Common Use

Synthesis of pharmaceutical compounds
Reagent in organic chemistry reactions

Potential Applications

Development of new drugs
Intermediate in the production of other chemical compounds

Upstream product

• 634198-01-9 5-benzyloxy-4-methoxy-2-nitrobenzoic acid benzyl ester 
• 31839-20-0 5-hydroxy-4-methoxy-2-nitrobenzoic acid 
• 26791-93-5 methyl 4,5-dimethoxy-2-nitrobenzoate 
• 148235-40-9 3-benzyloxy-4-methoxybenzoic acid benzyl ester 
• 100-39-0 benzyl bromide 
• 645-08-9 Isovanillic acid 

Downstream Products

• 1638151-52-6 (R)-2-((7-methoxy-4-(3-(quinoxaline-2-yloxy)-pyrrolidine-1-yl)-quinazoline-6-yl)-oxy)ethyl 4-methylbenzenesulphonate 
• 909912-09-0 benzyl 2-amino-5-(benzyloxy)-4-methoxybenzoic acid 
• 286371-64-0 6-(benzyloxy)-7-methoxyquinazolin-4(3H)-one 
• 634197-88-9 4-(6-benzyloxy-7-methoxy-quinazolin-4-yl)-piperazine-1-carboxylic acid (4-cyano-phenyl)-amide 
• 634197-93-6 {4-[4-(4-cyano-phenylcarbamoyl)-piperazin-1-yl]-7-methoxy-quinazolin-6-yloxy}-acetic acid methyl ester 
• 205259-46-7 4-(6-benzyloxy-7-methoxy-4-quinazolinyl)-1-piperazinecarboxylic acid tert-butyl ester 
• 286371-65-1 6-(benzyloxy)-4-chloro-7-methoxyquinazoline 

Relevant articles and documents

PDIA4 INHIBITORS AND USE THEREOF FOR INHIBITING ?-CELL PATHOGENESIS AND TREATING DIABETES

Disulfide-Isomerase A4 (PDIA4) inhibitors and use thereof for inhibiting pancreatic β-cell pathogenesis and treating diabetes are disclosed. Drug candidates that inhibit PDIA4 with IC50 values ranging from 4 μM to 300 nM are identified. The compounds are highly active in augmenting insulin secretion from pancreatic β-cells. The representative compound No. 8 (4,5-dimethoxy-2-propiolamidobenzoic acid), alone or in combination with metformin, is effective in preserving pancreatic β-cell function, treating and/or reversing, returning blood glucose concentration to a normal level in a diabetic.

Potent and Selective Inhibitors of Platelet-Derived Growth Factor Receptor Phosphorylation. 3. Replacement of Quinazoline Moiety and Improvement of Metabolic Polymorphism of 4-[4-(N-Substituted (thio)carbamoyl)-1-piperazinyl]-6,7-dimethoxyquinazoline Derivatives

We have previously reported that a series of 4-[4-(N-substituted (thio)carbamoyl)-1-piperazinyl]-6,7-dimethoxyquinazoline derivatives were potent and selective inhibitors of platelet-derived growth factor receptor (PDGFR) phosphorylation and demonstrated several biological effects such as suppression of neointima formation following balloon injury in rat carotid artery by oral administration. Here, we investigated structure-activity relationships of the 6,7-dimethoxyquinazolinyl moiety. In regard to 6,7-dimethoxy groups, ethoxy analogues showed potent activity (IC50 of 16b is 0.04 μM; IC50 of 17a is 0.01 μM) and further extension of the alkyl group reduced activity. Interestingly, methoxyethoxy (IC50 of 16j is 0.02μM; IC50 of 17h is 0.01 μM) and ethoxyethoxy (IC50 of 17j is 0.02 μM) analogues showed the most potent activity, suggesting that the inserted oxygen atom significantly interacts with β-PDGFR. Among tricyclic quinazoline derivatives, the 2-oxoimidazo[4,5-e]quinazoline derivative 21a showed potent activity (IC 50 = 0.10 μM). Regarding replacements of quinazoline by other heterocyclic rings, pyrazolo[3,4-d]pyrimidine (39a, IC50 = 0.17 μM) and quinoline (IC50 of 40a is 0.18 μM; IC50 of 40b is 0.09 μM) derivatives showed potent activity. Isoquinoline and some pyridopyrimidine derivatives were completely inactive; therefore, 1-aza has an important role. Also 7-aza and 8-aza substitution on the parent quinazoline ring has a detrimental effect on the interaction with β-PDGFR. We also demonstrated that the substituents on the quinazoline ring possess major consequences for metabolic polymorphism. Although there existed extensive metabolizers and poor metabolizers in Sprague-Dawley rats administrated 6,7-dimethoxyquinazoline derivatives (1b and 1c), 6-(2-methoxy)ethoxy-7-methoxyquinazoline analogue 16k showed no metabolic polymorphism.